Designing novel “Smell-Aids” to improve olfactory function in post COVID-19 era.

Publication date: Mar 24, 2025

Eyeglasses, hearing aids, etc. , all serve to enhance the sensory stimuli to enable patients to see or hear things that they would not otherwise be able to, but we have no equivalent technology for olfaction, a pressing issue in the post-COVID era. We attempt to invent “Smell-Aids” by non-invasively enhancing intranasal odorant delivery to the olfactory epithelium, using two prototypes: (a) a nasal foam plug with a diagonal channel embedded to direct air/odor flow upwards to the olfactory region; (b) a clip (similar to what synchronized swimmers use) pinching a critical nasal valve region that may intensify the nasal airflow vortex to the olfactory region. We first tested these prototypes in counter-balanced orders on 58 healthy subjects, where their measured odor detection thresholds to phenylethyl alcohol significantly improved with both prototypes in subjects with normal smell function (baseline: 8-16. 5, n = 30, 12. 49 +/- 2. 8, plug: 14. 42 +/- 4. 9, pinch: 14. 73 +/- 5. 4, p  16. 5, n = 28). Next, we tested the prototypes on 54 patients with confirmed olfactory losses (age 21-80 years, median 54. 5), the majority of whom (37/54 = 69%) were post-COVID long haulers (infected 12/15/2019 to 10/4/23; persisted 30 to 1260 days, median 22 months). The remaining non-COVID smell losses (n = 17) span significantly longer from 5 months to 27 years (median 8. 5 years). The 9-item NIH toolbox odor identification score significantly improved after application of both smell aids (baseline: 4. 30 +/- 2. 27, plug 5. 11 +/- 2. 32, pinch 4. 82 +/- 2. 06, mixed model p 

Open Access PDF

Concepts Keywords
27years Administration, Intranasal
Covid Adult
Odorant Aged
Swimmers Chronic COVID
Toolbox COVID-19
Female
Humans
Long COVID
Male
Middle Aged
Odorants
Olfaction Disorders
Olfactory dysfunction
PASC
SARS-CoV-2
Smell
Young Adult

Semantics

Type Source Name
disease MESH Aids
disease MESH COVID-19
drug DRUGBANK Medical air
drug DRUGBANK Phenylethyl alcohol
pathway REACTOME Reproduction
disease MESH hyposmia
disease MESH parosmia
disease MESH sequelae
disease MESH Long COVID
disease MESH inflammation
disease MESH Parkinson’s disease
disease IDO symptom
disease MESH infection
drug DRUGBANK Indoleacetic acid
disease MESH olfactory hallucination
disease MESH viral infection
disease MESH nasal obstruction
drug DRUGBANK Ethanol
drug DRUGBANK Esomeprazole
drug DRUGBANK Coenzyme M
disease MESH nasal polyps
disease MESH causes
drug DRUGBANK Mineral oil
drug DRUGBANK Isoxaflutole
drug DRUGBANK Trestolone
drug DRUGBANK Ademetionine
drug DRUGBANK Piroxicam
disease MESH sensorineural hearing loss
pathway REACTOME Sensory Perception
drug DRUGBANK Tropicamide
disease IDO intervention
disease IDO process
drug DRUGBANK Aspartame
disease MESH taste loss
drug DRUGBANK Tromethamine
disease MESH Allergy
disease MESH yawning
disease MESH Deafness
disease MESH Communication Disorders
disease MESH allergic rhinitis
disease MESH Asthma
pathway KEGG Asthma

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *